Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Indinavir · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Indinavir sulfate | DRUG | - |
| Levocarnitine | DRUG | - |
| Adefovir dipivoxil | DRUG | - |
| Lamivudine | DRUG | - |
| Stavudine | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Patients must have: * Laboratory diagnosis of HIV infection (positive HIV antibody test confirmed by Western blot, p24 antigen assay, HIV-1 RNA, or HIV-1 culture). * An HIV-1 RNA plasma titer \>= 5000 copies/ml within 14-21 days prior to the baseline visit. * CD4 cell count \>= ...
Top 20 of 28 competitors
Indinavir is a small molecule drug being studied for the treatment of HIV Infections. It is currently in Phase 2 clinical development and is being developed by Gilead Sciences, Inc. (GILD).
Indinavir is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The drug is currently in Phase 2 clinical development for HIV Infections.
Indinavir is in Phase 2 clinical development. It is an investigational drug being studied for the treatment of HIV Infections. It has completed one Phase 2 trial, and no active trials are currently listed.
Indinavir has been studied in one completed Phase 2 clinical trial, NCT00002379, which evaluated the safety and effectiveness of adefovir dipivoxil plus indinavir combined with zidovudine, lamivudine, or stavudine in HIV-infected patients who had not taken anti-HIV drugs. The trial enrolled 100 participants in the United States and Puerto Rico.
Indinavir is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of HIV Infections. It has completed one clinical trial, but approval status has not been established.